Stanford Nasal Vaccine Fights Viruses, Bacteria, Allergens

A New Vaccine Paradigm From Stanford

Scientists at Stanford Medicine have published what they describe as a fundamental challenge to 230 years of vaccine science. In a study released in February 2026 in the journal Science, a team led by immunologist Bali Pulendran demonstrated that a single nasal-spray formula could protect mice against a remarkably wide spectrum of threats — respiratory viruses, antibiotic-resistant bacteria, and even household allergens.

The research, whose lead author is postdoctoral scholar Haibo Zhang, drew contributions from Emory University, UNC Chapel Hill, Utah State University, and the University of Arizona. Its scope and ambition have drawn significant attention from the global scientific community.

How It Works: Rewiring the Immune System

Traditional vaccines work by presenting the immune system with a recognizable piece of a specific pathogen — a spike protein, a weakened virus — so the body can memorize and later defeat it. The Stanford formula takes an entirely different approach: it does not mimic any pathogen at all.

Instead, the vaccine — designated GLA-3M-052-LS+OVA — mimics the molecular signals that immune cells use to communicate with one another during an active infection. It stimulates toll-like receptors on innate immune cells and uses ovalbumin, an egg protein, to recruit T cells into the lungs. The result is a sustained feedback loop bridging both branches of immunity: innate and adaptive.

The key cellular players are macrophages — generalist white blood cells that patrol tissues for threats. The vaccine keeps them stationed in the lungs in what the researchers call an "amber alert" state: primed, watchful, and ready to respond to virtually any invader before it can gain a foothold.

Striking Results in Mice

The outcomes in animal trials were striking. Mice that received three intranasal doses showed:

• A 700-fold reduction in viral load in the lungs
• 100% survival against SARS-CoV-2 and related coronaviruses, compared with frequent death among unvaccinated controls
• Protection lasting at least three months against respiratory viruses, Staphylococcus aureus, and Acinetobacter baumannii — two bacteria notorious for causing deadly hospital-acquired infections
• Adaptive immune responses triggered in just three days, versus the two weeks typically required without vaccination
• Suppression of allergic reactions to house dust mite proteins, a common trigger of asthma and rhinitis

Vaccinated mice lost minimal weight and showed near-clear lungs, while their unprotected counterparts suffered severe illness.

Road to Human Trials

Pulendran has announced plans to move into Phase I clinical trials to assess safety in humans. He estimates that if funding proves adequate, a final version of the vaccine could reach patients within five to seven years — and that human protection might require as few as two doses of the nasal spray.

Not everyone is without reservations. Florian Krammer, an immunologist at Mount Sinai's Icahn School of Medicine, raised concerns that sustained immune activation might push the body's defenses to their limits, potentially causing unintended inflammation. He nonetheless supported proceeding to human testing.

The translational leap from mice to humans remains the defining challenge. Mouse immune systems differ substantially from human ones, and many promising animal studies have not survived clinical trials. Still, the breadth of protection observed — spanning viral, bacterial, and allergenic threats — has few precedents in vaccine research.

Implications for Global Health

If the approach holds in humans, the implications could be profound. A platform that primes the lungs against entire categories of pathogens — rather than one pathogen at a time — could reshape how societies prepare for pandemics, reduce dependence on annual reformulations, and offer new tools against drug-resistant bacteria. Stanford's nasal spray may be early-stage, but the idea it represents is already rewriting the rules.